These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 21177828)

  • 21. Pioglitazone attenuates hepatic inflammation and fibrosis in phosphatidylethanolamine N-methyltransferase-deficient mice.
    van der Veen JN; Lingrell S; Gao X; Quiroga AD; Takawale A; Armstrong EA; Yager JY; Kassiri Z; Lehner R; Vance DE; Jacobs RL
    Am J Physiol Gastrointest Liver Physiol; 2016 Apr; 310(7):G526-38. PubMed ID: 26797396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. More effective DPP4 inhibitors as antidiabetics based on sitagliptin applied QSAR and clinical methods.
    Buiu C; Avram S; Duda-Seiman D; Milac AL; Duda-Seiman C; Pacureanu L; Borcan F
    Curr Comput Aided Drug Des; 2014; 10(3):237-49. PubMed ID: 25756669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel thiazolidinedione analog reduces a negative impact on bone and mesenchymal stem cell properties in obese mice compared to classical thiazolidinediones.
    Benova A; Ferencakova M; Bardova K; Funda J; Prochazka J; Spoutil F; Cajka T; Dzubanova M; Balcaen T; Kerckhofs G; Willekens W; van Lenthe GH; Alquicer G; Pecinova A; Mracek T; Horakova O; Rossmeisl M; Kopecky J; Tencerova M
    Mol Metab; 2022 Nov; 65():101598. PubMed ID: 36103974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The peroxisome proliferator-activated receptor γ agonist pioglitazone preserves bone microarchitecture in experimental arthritis by reducing the interleukin-17-dependent osteoclastogenic pathway.
    Koufany M; Chappard D; Netter P; Bastien C; Weryha G; Jouzeau JY; Moulin D
    Arthritis Rheum; 2013 Dec; 65(12):3084-95. PubMed ID: 23982996
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of glycemic control, water retention, and musculoskeletal effects of balaglitazone and pioglitazone in diet-induced obese rats.
    Henriksen K; Byrjalsen I; Nielsen RH; Madsen AN; Larsen LK; Christiansen C; Beck-Nielsen H; Karsdal MA
    Eur J Pharmacol; 2009 Aug; 616(1-3):340-5. PubMed ID: 19595686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Understanding the molecular dynamics of type-2 diabetes drug target DPP-4 and its interaction with Sitagliptin and inhibitor Diprotin-A.
    Chakraborty C; Hsu MJ; Agoramoorthy G
    Cell Biochem Biophys; 2014 Nov; 70(2):907-22. PubMed ID: 24809328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
    Scheen AJ
    Clin Pharmacokinet; 2010 Sep; 49(9):573-88. PubMed ID: 20690781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and -independent pathways.
    Kim SJ; Nian C; McIntosh CH
    Diabetes; 2010 Jul; 59(7):1739-50. PubMed ID: 20368408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic role of dipeptidyl peptidase 4 (DPP4) in primary human (pre)adipocytes.
    Zilleßen P; Celner J; Kretschmann A; Pfeifer A; Racké K; Mayer P
    Sci Rep; 2016 Mar; 6():23074. PubMed ID: 26983599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice.
    Kim SJ; Nian C; Doudet DJ; McIntosh CH
    Diabetes; 2008 May; 57(5):1331-9. PubMed ID: 18299314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update).
    Gallwitz B
    Drugs Today (Barc); 2007 Nov; 43(11):801-14. PubMed ID: 18174966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.
    Gallwitz B
    Drugs Today (Barc); 2007 Jan; 43(1):13-25. PubMed ID: 17315049
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation.
    Kim SJ; Nian C; Doudet DJ; McIntosh CH
    Diabetes; 2009 Mar; 58(3):641-51. PubMed ID: 19073764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antidiabetic drug pioglitazone protects the heart via activation of PPAR-gamma receptors, PI3-kinase, Akt, and eNOS pathway in a rabbit model of myocardial infarction.
    Yasuda S; Kobayashi H; Iwasa M; Kawamura I; Sumi S; Narentuoya B; Yamaki T; Ushikoshi H; Nishigaki K; Nagashima K; Takemura G; Fujiwara T; Fujiwara H; Minatoguchi S
    Am J Physiol Heart Circ Physiol; 2009 May; 296(5):H1558-65. PubMed ID: 19286954
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sitagliptin Alters Bone Composition in High-Fat-Fed Mice.
    Mansur SA; Mieczkowska A; Flatt PR; Chappard D; Irwin N; Mabilleau G
    Calcif Tissue Int; 2019 Apr; 104(4):437-448. PubMed ID: 30564859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.
    Deacon CF
    Expert Opin Investig Drugs; 2007 Apr; 16(4):533-45. PubMed ID: 17371200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.
    Mu J; Woods J; Zhou YP; Roy RS; Li Z; Zycband E; Feng Y; Zhu L; Li C; Howard AD; Moller DE; Thornberry NA; Zhang BB
    Diabetes; 2006 Jun; 55(6):1695-704. PubMed ID: 16731832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cellular Sites and Mechanisms Linking Reduction of Dipeptidyl Peptidase-4 Activity to Control of Incretin Hormone Action and Glucose Homeostasis.
    Mulvihill EE; Varin EM; Gladanac B; Campbell JE; Ussher JR; Baggio LL; Yusta B; Ayala J; Burmeister MA; Matthews D; Bang KWA; Ayala JE; Drucker DJ
    Cell Metab; 2017 Jan; 25(1):152-165. PubMed ID: 27839908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term treatment with Sitagliptin, a dipeptidyl peptidase-4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced rats.
    Femia AP; Raimondi L; Maglieri G; Lodovici M; Mannucci E; Caderni G
    Int J Cancer; 2013 Nov; 133(10):2498-503. PubMed ID: 23649733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.